# Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

> **NCT02682641** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea** · enrollment: 50 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** IBRUTINIB
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02682641
- **Lead sponsor:** Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-18
- **Primary completion:** 2019-12
- **Final completion:** 2029-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682641, "Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02682641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*